GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

RN316

Company
Pfizer
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT00991159

    A Study To Access The Safety And Tolerability Of RN316 (PF-04950615) When Administered To Healthy Adult Subjects

    Not yet reported Pfizer 48 participants Est. completion 2010-05 2 sites Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Withdrawn NCT NCT01163838

    Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia

    Not yet reported Pfizer Est. completion 2011-03 Stand-alone
    Other conditions: Hypercholesterolemia, Dyslipidemia
    View official trial listing →
  • Completed NCT NCT01163851

    Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With Atorvastatin

    Not yet reported Pfizer 25 participants Est. completion 2011-04 5 sites Stand-alone
    Other conditions: Hypercholesterolemia, Dyslipidemia
    View official trial listing →
  • Completed NCT NCT01243151

    Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia

    Not yet reported Pfizer 68 participants Est. completion 2011-10 9 sites Stand-alone
    Other conditions: Hypercholesterolemia, Dyslipidemia
    View official trial listing →
  • Completed NCT NCT01342211

    A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins

    Not yet reported Pfizer 93 participants Est. completion 2012-06 44 sites Stand-alone
    Other conditions: Hypercholesterolemia, Dyslipidemia
    View official trial listing →
  • Completed NCT NCT01350141

    A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins

    Not yet reported Pfizer 46 participants Est. completion 2012-06 35 sites Stand-alone
    Other conditions: Hypercholesterolemia, Dyslipidemia
    View official trial listing →
  • Completed NCT NCT01435382

    A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia

    Not yet reported Pfizer 49 participants Est. completion 2012-04 7 sites Stand-alone
    Other conditions: Hypercholesterolemia, Dyslipidemias, Hyperlipidemias, Lipid Metabolism Disorders, Metabolic Diseases
    View official trial listing →
  • Completed NCT NCT01592240

    Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin

    Not yet reported Pfizer 354 participants Est. completion 2013-05 74 sites Stand-alone
    Other conditions: Hypercholesterolemia
    View official trial listing →
  • Completed NCT NCT01968954

    Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events

    Not yet reported Pfizer 711 participants Est. completion 2016-04 103 sites Stand-alone
    Other conditions: Hyperlipidemia
    View official trial listing →
  • Completed NCT NCT01968967

    Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events

    Not yet reported Pfizer 2139 participants Est. completion 2017-07-10 249 sites Stand-alone
    Other conditions: Hyperlipidemia
    View official trial listing →
  • Completed NCT NCT01968980

    A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia

    Not yet reported Pfizer 370 participants Est. completion 2016-04-15 88 sites Stand-alone
    Other conditions: Heterozygous Familial Hypercholesterolemia
    View official trial listing →
  • Terminated NCT NCT01975376

    The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

    Not yet reported Pfizer 16784 participants Est. completion 2017-03-22 1745 sites
    Cardiovascular disease
    View official trial listing →
  • Terminated NCT NCT01975389

    The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

    Not yet reported Pfizer 10564 participants Est. completion 2017-04-03 1595 sites
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT02043301

    Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm

    Not yet reported Pfizer 75 participants Est. completion 2014-11 6 sites Stand-alone
    Other conditions: Hypercholesterolemia
    View official trial listing →
  • Completed NCT NCT02055976

    Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects

    Not yet reported Pfizer 218 participants Est. completion 2015-01 9 sites Stand-alone
    Other conditions: Hypercholesterolemia
    View official trial listing →
  • Completed NCT NCT02100514

    Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events

    Not yet reported Pfizer 746 participants Est. completion 2017-07-10 223 sites Stand-alone
    Other conditions: Hyperlipidemia
    View official trial listing →
  • Completed NCT NCT02135029

    Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins

    Not yet reported Pfizer 184 participants Est. completion 2015-11 40 sites Stand-alone
    Other conditions: Hyperlipidemia
    View official trial listing →
  • Terminated NCT NCT02667223

    Pharmacokinetic and Pharmacodynamic Study of Bococizumab Alone and When Combined With Recombinant Human Hyaluronidase

    Not yet reported Pfizer 60 participants Est. completion 2016-07 1 site
    Other conditions: Healthy, Hypercholesterolemia
    View official trial listing →
  • Withdrawn NCT NCT02947334

    Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia Subjects

    Not yet reported Pfizer Est. completion 2019-05-03 1 site
    Other conditions: Primary Hyperlipidemia or Mixed Dyslipidemia
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.